Mbodies Pilates Instructor Training Academy

  The 2023 American Society for Clinical Oncology (ASCO) annual clinical meeting in cancer research showcased groundbreaking advances in Breast Cancer treatment. Among the plethora of clinical trial updates, two stand out as game-changers. Firstly, CDK4/6 inhibitors are taking a prominent position in Breast Cancer therapy.  Cyclin-dependent kinase 4 and 6 (CDK4 and CDK6) are enzymes important in cell division.  CDK4/6 inhibitors are drugs designed to interrupt the growth of cancer cells.  CDK4/6 inhibitors are used in combination with hormone therapy to treat some Breast Cancers.  These inhibitors block cancer cells' growth cycle, preventing cancer progression, and were initially developed as a treatment option for endocrine therapy-resistant Breast Cancer.  Palbociclib (Ibrance®) received American FDA approval in 2015, followed by ribociclib (Kisqali®) and abemaciclib (Verzenio®) in 2017 and in the UK NICE approved it in 2018.  Researchers presented trials with these inhibitors

  Prevalence of Osteoporosis and related fractures occurring in the UK Older women are naturally at the greatest risk of osteoporosis due to their increasing rate of bone loss caused by decreasing oestrogen production at the onset of the menopause. Development of Osteoporosis increases considerably from around 20% when aged 50 years to almost 50% when aged 80 years but many of these people will be completely unaware of their reduced bone density. One in two women and one in five men in the UK will sustain one or more osteoporotic fractures in their lifetime, and around 300,000 fragility fractures each year are the result of Osteoporosis.  Although far less common and somewhat preventable rather than a natural occurrence, it is also notable that adolescent, elite sportswomen of slight frame and body mass; for example, gymnasts and dancers may fail to accrue enough bone density when young, when peak bone mass should naturally be formed.  Somewhat paradoxically, over-exercising before

  Further to the development of online Pilates education in the UK, Mbodies is gaining a strong international presence as a Pilates Education Provider by introducing its video education content and assessment programmes in countries and languages other than English. Initial collaboration with TMSPilates studio, Budapest, introduces Mbodies Pilates Reformer Machine Education to Hungary, in the Hungarian language, and video content will be demonstrated alongside face-to-face practical interaction with students, in the studio.  TMS is the established regional distributor for Align-Pilates Reformers and as such, ideally placed to promote Pilates equipment-based training in their dedicated studio. The courses have been prepared for introduction in two phases: Phase 1 Initial training and assessment Initial training of local Hungarian tutors will be performed by Mbodies in order to train students in Hungary and assess them. TMSPilates use Mbodies tuition videos on screens in a studio for fac